MetaCap

Coherus Oncology (CHRS) vs ImageneBio (IMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImageneBio (IMA) has outperformed Coherus Oncology (CHRS) over the past year, losing 44.9% versus a loss of 68.1%. Over five years, IMA leads with a -97.9% price change compared with -98.0% for CHRS. Coherus Oncology is the larger company by market cap ($57.1 million vs $48.8 million), about 1.2 times the size.

Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus -5668.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CHRS-68.12%IMA-44.87%
+126%+24%-77%
Nov 21, 20251 yearNov 20, 2026
CHRS-98.00%IMA-97.89%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CHRS versus IMA key metrics
MetricCHRSIMA
Share price$0.3698$3.92
Market cap$57.15M$48.83M
1-day change-4.47%0.00%
YTD return-73.96%-43.19%
1-year return-68.12%-44.87%
5-year return-97.99%-97.86%
EPS (TTM)$-1.12$-2.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$42.17M$800.00K
Revenue growth (YoY)+59.81%-77.14%
Net income (latest FY)$168.02M$-45.35M
Gross margin67.24%—
Operating margin-429.51%-6056.38%
Net margin398.43%-5668.63%
52-week high$2.62$7.60
52-week low$0.3628$3.00
Distance from 52-week high-85.86%-48.42%
Analyst consensusstrong_buynone
Avg. price target upside+1995.73%+359.18%
Average volume1.80M15.86K
Shares outstanding154.54M12.46M
Employees14418
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMA has outperformed CHRS by 23.3 percentage points over the past year.
  • Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus -5668.6 cents for ImageneBio.
  • Coherus Oncology grew revenue faster in its latest fiscal year (+59.81% vs -77.14%).

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About ImageneBio

IMA stock →

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

CHRS vs IMA FAQ

Which is bigger, Coherus Oncology or ImageneBio?

Coherus Oncology (CHRS) is larger, with a market capitalization of $57.15M compared with $48.83M for ImageneBio (IMA).

Which stock has performed better over the past year, CHRS or IMA?

IMA returned -44.87% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.

Are Coherus Oncology and ImageneBio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons